Do acid-suppressing medications increase risk of SIBO and gut dysbiosis?

The use of acid-suppressing medications, particularly proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs), significantly alters the physiological environment of the gastrointestinal tract. While these medications are highly effective for treating acid-related disorders like GERD and peptic ulcers, they fundamentally modify the stomach's primary defense mechanism—the gastric acid barrier—leading to downstream changes in microbial composition.

Clinical evidence of SIBO and dysbiosis

Substantial evidence links the chronic use of acid suppressants to an increased risk of Small Intestinal Bacterial Overgrowth (SIBO) and systemic gut dysbiosis.

• SIBO Prevalence: Clinical studies indicate a higher prevalence of SIBO in patients using PPIs (30.4%) compared to non-users (27.0%). In high-risk populations, such as those with intestinal failure, the prevalence of SIBO among acid-suppressant users can reach as high as 72%.
• Microbial Diversity: Research consistently demonstrates that acid suppression leads to gut dysbiosis characterized by reduced alpha diversity (measured via Shannon and Simpson indices).
• Taxonomic Shifts: Microbiome profiling reveals a distinct shift toward the colonization of the gut by commensal oral bacteria, such as Streptococcaceae and Veillonellaceae, which normally cannot survive the acidic environment of the stomach.

Mechanistic explanations

The stomach serves as a "gatekeeper" through the production of hydrochloric acid (HCl), which maintains a fasting pH typically between 1.0 and 3.0.

• Bactericidal Threshold: A gastric pH of less than 4.0 is required to achieve a 99.9% kill rate of ingested pathogens within 30 minutes. PPIs often raise intragastric pH to levels between 4.0 and 6.0, effectively eliminating this bactericidal effect.
• Survival and Migration: When acidity is reduced (hypochlorhydria), pathogens like Salmonella, Shigella, and Escherichia coli survive transit through the stomach. This allows for the migration and proliferation of both oral-derived and environmental microbes into the small intestine, where they compete for nutrients and produce gases (hydrogen and methane).

Clinical implications and safety

The weakening of the gastric barrier has broader implications for infection risk and long-term health, particularly in older populations.

• Pathogen Susceptibility: Patients on acid suppressants are at a significantly higher risk for enteric infections, including Clostridioides difficile, due to the survival of spores and vegetative cells that would otherwise be neutralized by stomach acid.
• Multidrug Resistance: Hypochlorhydria is associated with increased colonization by multidrug-resistant organisms (MDROs) in the gut, as the loss of the acid barrier facilitates the establishment of exogenous, resistant bacterial strains.
• Nutritional Impact: The presence of SIBO can lead to malabsorption of fats and vitamins (particularly B12), which is of significant concern for older adults who may already face nutritional vulnerabilities.

Bottom line

Acid-suppressing medications increase the risk of SIBO and gut dysbiosis by raising gastric pH above the critical bactericidal threshold of 4.0. This compromises the stomach's role as a microbial barrier, allowing for the overgrowth of oral-derived bacteria and pathogens in the small intestine. For older patients, the benefits of long-term PPI use should be weighed against the potential for altered gut ecology and increased susceptibility to enteric infections.